Physician profile
Ashwin Gowda
NPI 1669447397
$70,855.78
in general payments reported to CMS, 2019-2025
17 companies · $44K in 2025
The $44K reported for 2025 was more than what 95% of Sleep Medicine (Psychiatry & Neurology) providers received nationally (typical 2025 total: $337).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $654 · 2020: $390 · 2021: $1,118 · 2022: $9,616 · 2023: $12K · 2024: $3,283 · 2025: $44K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $40K · Consulting Fee: $8,370 · Food and Beverage: $5,126 · Travel and Lodging: $3,752 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,875 · Education: $54.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $39,900.00 |
| Consulting Fee | $8,370.00 |
| Food and Beverage | $5,126.12 |
| Travel and Lodging | $3,751.89 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,875.00 |
| Education | $54.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $41,427.10 | 2025 | Zepbound, Mounjaro |
| Axsome Therapeutics, INC. | $11,370.50 | 2023-2025 | Sunosi |
| Jazz Pharmaceuticals INC. | $9,724.63 | 2019-2024 | |
| Inspire Medical Systems, INC. | $5,095.03 | 2020-2025 | Inspire |
| Zoll Respicardia, INC. | $1,726.62 | 2023-2025 | Remede System |
| Avadel Cns Pharmaceuticals, LLC | $360.19 | 2023-2025 | Lumryz |
| Harmony Biosciences LLC | $300.60 | 2020-2024 | Wakix |
| Eisai INC. | $229.76 | 2020-2022 | |
| Ironshore Pharmaceuticals INC. | $148.03 | 2019 | |
| Idorsia Pharmaceuticals US INC | $105.62 | 2023-2025 | Quviviq, Quviviq |
| Teleflex LLC | $104.99 | 2024 | Urolift |
| Arbor Pharmaceuticals, INC. | $92.60 | 2019-2022 | |
| Watermark Medical, INC. | $84.98 | 2021 | |
| Philips North America LLC | $31.34 | 2025 | Sleepundivided |
| Currax Pharmaceuticals LLC | $23.47 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Azurity Pharmaceuticals, INC. | $18.11 | 2025 | Edarbi |
| Merck Sharp & Dohme LLC | $12.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashwin Gowda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.